Synthesis, purification, and properties of a peptide that enhances the activation of human [Glu1]plasminogen by tissue plasminogen activator and retards fibrin polymerization

Solid phase synthesis of the hexapeptide, GPRVVE, which represents the amino terminal six amino acids of the alpha-chain of human fibrin, yielded a product that contained a modified glutamic acid. The nature of the modification was established as the Friedel-Crafts acylation product of the peptide and anisole, the latter reagent employed in the HF deblocking step. The anisoylated peptide selectively enhanced the activation rate of native [Glu1]plasminogen by recombinant tissue plasminogen activator, accelerated clot lysis, and retarded the polymerization of nascent fibrin.